| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/28/2009 | US7524495 Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation |
| 04/28/2009 | US7524494 Degradation of hydrophobic ester pesticides and toxins |
| 04/28/2009 | US7524493 Nucleic acid constructs cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension |
| 04/28/2009 | US7524490 Clusterin-mediated inhibition of apoptosis via stromal bone marrow cell delivery to a cardiac site |
| 04/28/2009 | US7524488 Interleukin-18 mutants |
| 04/28/2009 | US7524487 Contacting cell with a composition comprising extracellular-signal-regulated kinase (ERK) activating agent in combination with a phosphatase inhibitor; treating inflammation |
| 04/28/2009 | CA2429793C Interferon therapeutic effect enhancer |
| 04/28/2009 | CA2418506C Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| 04/28/2009 | CA2361424C Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| 04/28/2009 | CA2339765C Compounds and compositions for delivering active agents |
| 04/28/2009 | CA2279530C A method for the detection and localization of ductal exocrine pancreas tumours |
| 04/28/2009 | CA2222964C Oxygen activatable formulations for disinfection or sterilization |
| 04/28/2009 | CA2220195C Therapeutic oligonucleotides targeting the human mdr1 and mrp genes |
| 04/28/2009 | CA2219988C Cd16-ii variants |
| 04/28/2009 | CA2212382C Cochleate delivery vehicles |
| 04/28/2009 | CA2135614C Use of urodilatin in pulmonary and bronchial diseases |
| 04/26/2009 | CA2641830A1 Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders |
| 04/23/2009 | WO2009052489A2 Novel inhibitors of mammalian tight junction opening |
| 04/23/2009 | WO2009052478A1 Metabolic and cardioprotection by the myokine follistatin-like 1 polypeptide |
| 04/23/2009 | WO2009052449A1 Novel peptides and uses thereof |
| 04/23/2009 | WO2009052411A2 Methods for treatment of thiol-containing compound deficient conditions |
| 04/23/2009 | WO2009052379A2 Improved antitumoral treatments |
| 04/23/2009 | WO2009052323A2 Manufacture, compositions and uses of coagulationfactor viia modulator |
| 04/23/2009 | WO2009052293A1 Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
| 04/23/2009 | WO2009052211A1 Compositions and methods for enhancing lymphangiogenesis |
| 04/23/2009 | WO2009052184A2 Compositions comprising optimized her1 and her3 multimers and methods of use thereof |
| 04/23/2009 | WO2009052140A1 Use of tnf receptor antagonists for treating dry eye |
| 04/23/2009 | WO2009051992A1 Compositions and methods for treating diseases involving ocular angiogenesis by inhibiting one or more selected receptor tyrosine kinases |
| 04/23/2009 | WO2009051845A2 Biodegradable implants with controlled bulk density |
| 04/23/2009 | WO2009051717A2 Human factor ix variants with an extended half life |
| 04/23/2009 | WO2009051706A2 Peptide compounds for treating obesity and insulin resistance |
| 04/23/2009 | WO2009051599A1 Use of biomarkers of alzheimer's disease for diagnostic tests and drug screening |
| 04/23/2009 | WO2009051581A1 Proteasome inhibitors |
| 04/23/2009 | WO2009051213A1 Therapeutic agent for leukoderma and method for acceleration of pigmentation |
| 04/23/2009 | WO2009050743A1 Pharmaceutical composition comprising ecballium elaterium juice and their use in medical field |
| 04/23/2009 | WO2009050486A2 F0xp3 : nfat inhibitor peptides for the treatment of cancer |
| 04/23/2009 | WO2009050403A2 Patch with hydrophilic adhesive |
| 04/23/2009 | WO2009050296A1 Improved antitumoral treatments |
| 04/23/2009 | WO2009050279A1 Peptides based on the sequence of human lactoferrin and their use |
| 04/23/2009 | WO2009050275A1 A protease-sensitive site in apolipoprotein a1, therapeutic and diagnostic implications |
| 04/23/2009 | WO2009050267A2 Il24 for inducing hyperproliferative or autoimmune cell death |
| 04/23/2009 | WO2009049917A1 Kit ligand for use in the treatment of beta-thalassaemia |
| 04/23/2009 | WO2009049914A2 Novel patient subgroups for thrombolysis |
| 04/23/2009 | WO2009049406A1 Use of ps20 /wfdc1 and interferons to diagnose, monitor and treat viral diseases |
| 04/23/2009 | WO2009030498A3 Use of gip for the treatment of disorders associated with dysfunctional synaptic transmission |
| 04/23/2009 | WO2009029235A3 Peptides and proteins for early liver development and anitibodies thereto, and their use in therapeutic diagnosis and treatment |
| 04/23/2009 | WO2009027823A3 Pharmaceutical composition for selective stimulation of wound healing processes, dermal-epidermal normal tissular trophism processes, its preparation and application. |
| 04/23/2009 | WO2009026233A3 Self assembling peptide systems and methods |
| 04/23/2009 | WO2009025763A3 Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| 04/23/2009 | WO2009024667A3 Antitumour combinations containing a vegf inhibiting agent and irinotecan |
| 04/23/2009 | WO2009012958A3 Tubulysin d analogues |
| 04/23/2009 | WO2009010765A3 Lantibiotic-based compounds having antimicrobial activity |
| 04/23/2009 | WO2009009019A3 Treatment and diagnostic methods for fibrosis related disorders |
| 04/23/2009 | WO2008157425A3 Compounds for inhibiting protein aggregation, and methods for making and using them |
| 04/23/2009 | WO2008156725A3 Methods for inhibiting cartilage mineralization |
| 04/23/2009 | WO2008156428A3 Novel peptides and protein and uses thereof |
| 04/23/2009 | WO2008140603A3 METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| 04/23/2009 | WO2008062288A3 Poly-tlr antagonist |
| 04/23/2009 | WO2008038287A3 N-terminal fgf variants having increased receptor selectivity and uses thereof |
| 04/23/2009 | WO2007149827A3 Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
| 04/23/2009 | WO2007119201A3 Novel antibacterial compounds |
| 04/23/2009 | WO2007116410A3 Livestock management for improved reproductive efficiency |
| 04/23/2009 | WO2007102081A3 Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines |
| 04/23/2009 | WO2007058678A3 Uses of pegylated albumin |
| 04/23/2009 | WO2007056362A3 Glucagon analogs exhibiting physiological solubility and stability |
| 04/23/2009 | WO2007050130A3 Gold surfaces coated with a thermostable, chemically resistant polypeptide layer and applications thereof |
| 04/23/2009 | WO2007047811A3 Improved reproductive management |
| 04/23/2009 | WO2007046893A3 Methods for generating bioactive assemblies and uses thereof |
| 04/23/2009 | WO2007044940A3 Antibody against a peptide derived from human mutant lamin a protein and uses thereof |
| 04/23/2009 | WO2007044534A3 Vegf analogs and methods of use |
| 04/23/2009 | WO2007044450A3 Compositions and methods for the treatment of cancer |
| 04/23/2009 | WO2007041610A3 Genes and proteins associated with angiogenesis and uses thereof |
| 04/23/2009 | WO2007041213A3 Methods for regulation of p53 translation and function |
| 04/23/2009 | WO2007028147A3 Identification of a prostatic intraepithelial neoplasia (pin)-specific gene and protein (pin-1) useful as a diagnostic treatment for prostate cancer |
| 04/23/2009 | WO2007019426A3 A novel peptide involved in energy homeostasis |
| 04/23/2009 | WO2007014193A3 Peptidyl diacylglycerides |
| 04/23/2009 | WO2007005787A3 Methods and compositions for keratinocyte culture and therapeutics |
| 04/23/2009 | WO2007005786A3 Methods and compositions with enhanced therapeutic activity |
| 04/23/2009 | WO2007005645A3 Materials and methods for the generation of fully 2'-modified nucleic acid transcripts |
| 04/23/2009 | WO2006133333A3 Stimulation of pancreatic b cell proliferation |
| 04/23/2009 | WO2006121633A3 Activation of the dax-1 and shp nuclear orphan receptors |
| 04/23/2009 | WO2006112879A3 Hunk, a snf1-related kinase essential for mammary tumor metastasis |
| 04/23/2009 | WO2006110490A3 Agents and methods for osteogenic oxysterols inhibition of oxidative stress on osteogenic cellular differentiation |
| 04/23/2009 | WO2006107387A3 Wound treatment device for photodynamic therapy and method of using same |
| 04/23/2009 | WO2006105538A3 Methods and compositions for treating il-21 related pathologies |
| 04/23/2009 | WO2006102267A3 New neuronal pain pathway |
| 04/23/2009 | WO2006102070A3 Sclerostin and the inhibition of wnt signaling and bone formation |
| 04/23/2009 | WO2006094116A3 Enzyme sensors including environmentally sensitive or fluorescent labels and uses thereof |
| 04/23/2009 | WO2006071843A3 Biomarkers for breast cancer |
| 04/23/2009 | WO2006041631A3 Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| 04/23/2009 | WO2005100384A3 Ai-2 compounds and analogs based on salmonella typhimurium lsrb structure |
| 04/23/2009 | WO2005077084A3 Krüppel-like transcriptional factor klf4/gklf and uses thereof |
| 04/23/2009 | WO2004028479A9 Nouvelles compositions et methodes de traitement du psoriasis |
| 04/23/2009 | US20090106852 Influenza Therapeutic |
| 04/23/2009 | US20090105471 Macrocyclic compounds as inhibitors of viral replication |
| 04/23/2009 | US20090105467 Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues |
| 04/23/2009 | US20090105464 Physiologically active polypeptide and dna |
| 04/23/2009 | US20090105453 Expression vectors; transformed host cells; culturing the host cell to produce the encoded polypeptide; antiasthmatic agents |
| 04/23/2009 | US20090105193 Crosslinked compounds and methods of making and using thereof |
| 04/23/2009 | US20090105185 Nucleosides with anti-hepatitis B Virus activity |